Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

The device demonstrated a detection limit of 30 copies/mL of HIV RNA, a level comparable to traditional laboratory methods, with no cross-reactivity to hepatitis C virus (HCV). Clinical testing ...

registry study demonstrating the efficacy and safety of ibalizumab in reducing HIV RNA to undetectable levels in heavily treatment-experienced (HTE) patients with multidrug resistant HIV. In a poster ...

The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.